JuliaHornig Ph.D.


Munich +

Dr. Julia Hornig is a German patent attorney and is currently training as a European patent attorney in the areas of molecular virology, life sciences, biotechnology, and pharmaceuticals.

Julia has in-depth technical experience in the fields of recombinant viral vaccines and T cell biology. She has taken part in oral proceedings before the Examination and Opposition Divisions of the European Patent Office (EPO). She has also experience in intellectual property right infringement proceedings before the national German courts.

Prior to joining Jones Day in 2017, Julia worked as a postdoctoral research associate at Texas A&M University in the field of Cytomegalovirus (CMV) research and vaccine development. During this time she gained valuable experience in the fields of bacterial artificial chromosome (BAC) technology, virology, and immunology. In particular, her research focused on the essential role of IE1 and IE2 in viral replication and IE1-mediated ND10 targeting.

She has coauthored several peer-reviewed scientific articles, which have been published in journals such as Blood, Virology, and PLoS One.


  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Additional Publications

    Publications Prior to Jones Day


    The essential role of guinea pig cytomegalovirus (GPCMV) IE1 and IE2 homologs in viral replication and IE1-mediated ND10 targeting. Virology. 2017. 504:122-140.


    Viral Glycoprotein Complex Formation, Essential Function and Immunogenicity in the Guinea Pig Model for Cytomegalovirus; PLoS One. 2015. 10(8): e0135567.


    Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach. Expert Opin Drug Discov. 2014. 9(8):891-915.


    CD34-derived human Langerhans cells stimulate a T helper type 2 response independently of extracellular-signal-regulated kinase phosphorylation. Immunology. 2010. 131(2):210-9. doi: 10.1111/j.1365-2567.2010.03295.x. 


    Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A. 2009. 106(47):19940-5. 

    TLR-stimulated CD34 stem cell-derived human skin-like and monocyte-derived dendritic cells fail to induce Th17 polarization of naive T cells but do stimulate Th1 and Th17 memory responses. J Immunol. 2009. 183(4):2242-51.